Role of inflammatory factors in the etiology and treatment of recurrent implantation failure
review
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
This paper examines the role of inflammation in recurrent implantation failure and discusses potential treatments targeting these inflammatory factors.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Recurrent implantation failure (RIF) is characterized by the absence of implantation after high-grade embryos are transferred to the endometrium by at least three in vitro fertilization cycles. It is one of the most important factors contributing to reproductive failure. After numerous barriers have been overcome to obtain good-quality embryos, RIF causes extreme distress and frustration in women and couples. In recent years, significant progress has been made in understanding how inflammatory factors, which include pro-inflammatory factors, anti-inflammatory factors, chemokines, and other molecules, contribute to RIF. Immunological abnormalities, hypercoagulability, and reproductive diseases are considered potential causes of RIF. In alloimmune disorders, inflammatory factors can affect the success rate of embryo implantation by altering T helper (Th)1/Th2 and Th17/regulatory T cell ratios and causing imbalances of uterine natural killer cells and macrophages. Autoimmune disorders can also lead to RIF. Inflammatory factors also play key roles in RIF-related disorders such as hypercoagulability, chronic endometritis, adenomyosis, hydrosalpinx, and endometriosis. This review focuses on the roles of inflammatory factors in RIF, including immune factors, blood hypercoagulable states, and reproductive diseases such as chronic endometritis, adenomyosis, hydrosalpinx, and endometriosis. It also summarizes the different treatments according to the causes of RIF and discusses the efficacy of sirolimus, peripheral blood mononuclear cells, low-dose aspirin combined with low-molecular-weight heparin, blocking interleukin-22, and gonadotropin-releasing hormone agonists in the treatment of RIF.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (78)
- Analysis of IVF/ICSI Outcomes in Endometriosis Patients With Recurrent Implantation Failure: Influence on Cumulative Live Birth Rate via openalex
- Association of miRNA-145 with the occurrence and prognosis of hydrosalpinx-induced defective endometrial receptivity via openalex
- Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells. via openalex
- Clinical Management of Endometriosis via openalex
- Decreased Endometrial IL-10 Impairs Endometrial Receptivity by Downregulating HOXA10 Expression in Women with Adenomyosis via openalex
- Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy via openalex
- The Delicate Balance between the Good and the Bad IL-1 Proinflammatory Effects in Endometriosis via openalex
- The Disease Phenotype of Adenomyosis-Affected Women Correlates With Specific Serum Cytokine Profiles via openalex
- The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. II: adenomyosis and macrophages via openalex
- W2073453673 via openalex
- W2074471160 via openalex
- W2087518307 via openalex
- W2097222243 via openalex
- W2133031521 via openalex
- W2152059150 via openalex
- W2276863329 via openalex
- W2295733001 via openalex
- W2435143021 via openalex
- W2461455802 via openalex
- W2498757346 via openalex
- W2515052691 via openalex
- W2521855977 via openalex
- W2547791325 via openalex
- W2569771289 via openalex
- W2569817636 via openalex
- W2609947807 via openalex
- W2738729587 via openalex
- W2801471902 via openalex
- W2836133669 via openalex
- W2889070550 via openalex
- W2902048783 via openalex
- W2903206197 via openalex
- W2906410933 via openalex
- W2921091918 via openalex
- W2921504312 via openalex
- W2954213841 via openalex
- W2957935794 via openalex
- W2959185092 via openalex
- W2962770187 via openalex
- W2975146716 via openalex
- W2980325747 via openalex
- W2981403764 via openalex
- W2989220740 via openalex
- W2989355420 via openalex
- W3011719562 via openalex
- W3012037003 via openalex
- W3034657359 via openalex
- W3087095807 via openalex
- W3088061485 via openalex
- W3094129766 via openalex
- W3111083441 via openalex
- W3138949369 via openalex
- W3145278406 via openalex
- W3145351346 via openalex
- W3166690424 via openalex
- W3189633116 via openalex
- W3200012024 via openalex
- W3202601004 via openalex
- W3216908289 via openalex
- W4200435420 via openalex
- W4210261475 via openalex
- W4210960101 via openalex
- W6630470650 via openalex
- W6688951627 via openalex
- W6760466766 via openalex
- W6769124188 via openalex
- W6775844072 via openalex
- W6800487167 via openalex
- W1498729905 via openalex
- W6808604841 via openalex
- W1507312029 via openalex
- W1911501407 via openalex
- W1928535102 via openalex
- W1968889271 via openalex
- W2000174251 via openalex
- W2015821770 via openalex
- W2053854495 via openalex
- W2067960120 via openalex
Cited by (2)
Source provenance
- europepmc
- last seen: 2026-07-26T06:08:39.051465+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-07-26T06:08:24.388272+00:00
License: CC0
· commercial use OK